Company news
Cytomx Therapeutics, Inc. (NASDAQ:CTMX) news
Cytomx Therapeutics, Inc. news releases on 6ix. Latest, Aug 27, 2026: CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan…
Press releases & updates
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)
August 27, 2026
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
August 6, 2026
CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer
August 3, 2026
CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
July 30, 2026
CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors
July 27, 2026
CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
June 2, 2026
CytomX Therapeutics to Present at Upcoming June Investor Conferences
May 21, 2026
CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs
May 18, 2026
CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update
May 7, 2026
CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
April 30, 2026
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
March 16, 2026
CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
March 16, 2026
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
March 15, 2026
CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026
March 3, 2026
CytomX Therapeutics to Present at Upcoming February Conferences
February 4, 2026
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development
January 27, 2026
Wareham Development Leases Full Floor at EmeryStation Research Campus to CytomX Therapeutics
January 21, 2026
CytomX Therapeutics Announces Business Update and Company Milestones for 2026
January 7, 2026
CytomX Therapeutics to Present at Upcoming December Investor Conferences
November 24, 2025
CytomX Therapeutics to Present at the Jefferies London Healthcare Conference
November 12, 2025
CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
November 5, 2025
CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 3, 2025
CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025
October 29, 2025
CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer
October 19, 2025
CytomX Therapeutics to Present at Upcoming September Investor Conferences
August 27, 2025
CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study
August 12, 2025
CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
August 6, 2025
CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025
July 30, 2025
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
May 28, 2025
CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma
May 18, 2025
CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
May 11, 2025
CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
May 11, 2025
CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)
May 11, 2025
CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025
May 4, 2025
CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting
April 27, 2025
CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update
March 5, 2025
CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference
March 4, 2025
CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
February 26, 2025
CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 7, 2025
CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update
January 5, 2025
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
November 26, 2024
CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 6, 2024
CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
October 30, 2024
CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors
September 8, 2024
CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 7, 2024
CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024
July 31, 2024
CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
June 17, 2024
CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer
June 16, 2024
CytomX Therapeutics Announces New Employment Inducement Grants
May 15, 2024
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 7, 2024